Zevra Therapeutics develops and sells treatments for rare diseases, including MIPLYFFA for Niemann Pick disease type C. It last closed at $8.76 on Nov 20, down 3.42% on the day. The next earnings report for ZVRA is expected around Mon, Mar 8, 2027, after the close. For the quarter ended Sep 2026, ZVRA reported EPS of $0.26 on revenue of $37.8M, with revenue up 44.9% from a year ago. Over its last 8 reports the stock moved an average of 10.0% the session after earnings. Over the last 12 months ZVRA insiders bought $0 of stock on the open market and sold $2.5M, according to SEC Form 4 filings.
AI Auto Pilots
Is ZVRA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ZVRA.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on ZVRAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
ZVRA · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 18% below its 20 day and 22% below its 50 day average. It is 24% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot S1 at $8.57, and the nearest resistance the Pivot at $8.89.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.1%/day
Key levels
$15.0452 week high+71.7%
$11.29100 day average+28.9%
$10.85200 day average+23.9%
$10.6850 day average+21.9%
$10.55Swing high (Oct 29)+20.4%
$10.3020 day average+17.6%
$9.07Pivot R1+3.5%
$8.89Pivot+1.5%
$8.76Last close
$8.57Pivot S1−2.2%
$8.0152 week low−8.6%
Indicators
RSI (14)
35.54
Weak, oversold below 30
Neutral
MACD
-0.41
Below its signal line
Bearish
Stochastic
5.8
Near the bottom of its range
Oversold
ADX (14)
23.8
Weak trend
Williams %R
-98.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-121.7
Oversold below −100, overbought above 100
Oversold
Rate of change
−24.4%
Change over 10 sessions
Bearish
ATR (14)
$0.62
Typical daily range, 7.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 16.3%/day
Key levels
$15.0452 week high+71.7%
$11.29100 day average+28.9%
$10.85200 day average+23.9%
$10.6850 day average+21.9%
$10.55Swing high (Oct 29)+20.4%
$10.3020 day average+17.6%
$9.07Pivot R1+3.5%
$8.89Pivot+1.5%
$8.76Last close
$8.57Pivot S1−2.2%
$8.0152 week low−8.6%
Indicators
RSI (14)
41.54
Middle of its range
Neutral
MACD
-0.31
Below its signal line
Bearish
Stochastic
21.7
Middle of its range
Neutral
ADX (14)
18.3
No clear trend
Williams %R
-98.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-153.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−27.1%
Change over 10 sessions
Bearish
ATR (14)
$1.43
Typical daily range, 16.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for ZVRA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ZVRA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow ZVRA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for ZVRAHow many large options trades hit ZVRA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in ZVRA in the last 90 days.
From SEC Form 4 filings by ZVRA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZVRA is in one of them and how their past ZVRA trades turned out.
Zevra Therapeutics develops and sells medicines for rare diseases. Its main approved products are MIPLYFFA, an oral treatment for Niemann Pick disease type C, and OLPRUVA, used to help manage urea cycle disorders in adults and children. The company also has candidates in clinical development, including celiprolol for vascular Ehlers Danlos syndrome. Its products are sold mainly to patients and providers in the United States, and MIPLYFFA is also made available to patients in parts of Europe through an access program. The company is based in Boston, Massachusetts.